CA096997/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	1
2009	2
2011	2
2012	3
2013	2
2014	1
2015	5
2016	4
2017	1
2022	0

1

Dendritic cell-based vaccines: barriers and opportunities.

Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Cintolo JA, et al. Future Oncol. 2012 Oct;8(10):1273-99. doi: 10.2217/fon.12.125. Future Oncol. 2012. PMID: 23130928 Free PMC article. Review.

2

Reengineering dendritic cell-based anti-cancer vaccines.

Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Koski GK, et al. Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x. Immunol Rev. 2008. PMID: 18364007 Review.

3

Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Roses RE, Datta J, Czerniecki BJ. Roses RE, et al. Radiat Res. 2014 Aug;182(2):211-8. doi: 10.1667/RR13495.1. Epub 2014 Jul 3. Radiat Res. 2014. PMID: 24992163 Free PMC article. Review.

4

Sentinel lymph node biopsy in breast cancer: a work in progress.

Chatterjee A, Serniak N, Czerniecki BJ. Chatterjee A, et al. Cancer J. 2015 Jan-Feb;21(1):7-10. doi: 10.1097/PPO.0000000000000090. Cancer J. 2015. PMID: 25611773 Free PMC article. Review.

5

Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy.

Terhune J, Berk E, Czerniecki BJ. Terhune J, et al. Vaccines (Basel). 2013 Nov 21;1(4):527-49. doi: 10.3390/vaccines1040527. Vaccines (Basel). 2013. PMID: 26344346 Free PMC article. Review.

6

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

De La Cruz LM, Nocera NF, Czerniecki BJ. De La Cruz LM, et al. Immunotherapy. 2016 Oct;8(10):1219-32. doi: 10.2217/imt-2016-0052. Immunotherapy. 2016. PMID: 27605070 Free PMC article. Review.

7

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Front Immunol. 2015. PMID: 26082780 Free PMC article. Review.

8

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ. Nocera NF, et al. Front Pharmacol. 2016 Oct 6;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016. Front Pharmacol. 2016. PMID: 27766079 Free PMC article. Review.

9

CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ Jr, Czerniecki BJ. Datta J, et al. Cancer Immunol Res. 2015 May;3(5):455-63. doi: 10.1158/2326-6066.CIR-14-0208. Epub 2015 Mar 19. Cancer Immunol Res. 2015. PMID: 25791067 Free PMC article.

10

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER^pos/HER2^pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Lowenfeld L, et al. Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017. Oncoimmunology. 2016. PMID: 28932627 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results